Autres langues Crinetics Pharmaceuticals, Inc.

Actions

CRNX

US22663K1079

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/05/2024			Varia. 5j.	Varia. 1 janv.
48 ^USD	-2,87 %		+1,69 %	+34,91 %

10/05	Un initié de Crinetics Pharmaceuticals a vendu des actions pour une valeur de 5 307 931 $, selon un récent dépôt auprès de la SEC	MT
09/05	Crinetics Pharmaceuticals aggrave sa perte nette au premier trimestre	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	10/05
Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing	10/05
Crinetics Pharmaceuticals Q1 Net Loss Widens	09/05
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024	08/05
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024	02/05
Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	17/04
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	11/04
Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing	26/03
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing	22/03
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing	22/03
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing	21/03
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	19/03
Correction: Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell	19/03
Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell	19/03
Crinetics Pharmaceuticals : Topline Results from Paltusotine Phase 3 PATHFNDR-2 Study	19/03
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study	19/03
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients	19/03
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly	19/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Crinetics Pharmaceuticals, Inc.

Actions

CRNX

US22663K1079

Autres langues

Filtres